http://www.who.int/medicines/publications/druginformation/issues/Proposed-List_109.pdf str is available in this link
20,20,21,21,21-pentafluoro-17-hydroxy-11β-[4-
(methanesulfonyl)phenyl]-19-nor-17α-pregna-4,9-dien-3-one
progesterone receptor antagonist
BAY 1002670, vilaprisan
1262108-14-4
C27H29F5O4S, 544.574
http://www.who.int/medicines/publications/druginformation/issues/Proposed-List_109.pdf str is available in this link
Bayer has also made good progress in the development of new treatment options for patients with gynecological diseases: sPRM (BAY 1002670) is a novel oral progesterone receptor modulator that holds the promises of long-term treatment of patients with symptomatic uterine fibroids. Based on promising early clinical data the initiation of a Phase III study is planned for mid-2014.
A selective progesterone receptor modulator (SPRM) is an agent that acts on the progesterone receptor. A characteristic that distinguishes such substances from receptor full agonists (such as progesterone) and full antagonists (such as mifepristone) is that their action differs in different tissues (agonist in some while antagonist in others). This mixed agonist/antagonist profile of action leads to selective stimulation or inhibition progesterone-like action in different tissues and furthermore raises the possibility of dissociation of desirable therapeutic effects from undesirable side effects in synthetic progesterone receptor drug candidates
amcrasto@gmail.com
email me if u like my posts
Reblogged this on MariaGairos–DRUGS.
Reblogged this on Med.Chem in Nepal.